Indian semaglutide biosimilars: what they are, how they work, and who they are for

It is a DCGI-approved Indian-manufactured product containing the same semaglutide molecule as the imported originator, sold under an Indian brand name at a far lower price. More than forty manufacturers launched such products from 21 March 2026, the day after the core Indian patent expired [5][7].

A point of accuracy: these products are widely called biosimilars in everyday conversation and in the press, but semaglutide is a chemically synthesised peptide rather than a large biologic protein. Regulators therefore approve these as generics, demonstrating equivalence to the reference product, rather than through the biosimilar pathway used for antibodies and insulins. The practical result is the same, an identical molecule at a lower price, but the correct term is generic.

The major manufacturers and their brands include [5][6][7]:

• Sun Pharma — Noveltreat (chronic weight management, pre-filled pen) and Sematrinity (type 2 diabetes, multi-dose pen).
• Eris Lifesciences — SUNDAE, a vial format and among the lowest-priced semaglutide products anywhere.
• Alkem Laboratories — Obesema (weight management), Semasize and Hepaglide, in a pre-filled disposable pen holding four weekly doses, with a reusable pen option also available.
• Zydus Lifesciences — Semaglyn, Mashema and Alterme, notable for a cartridge-based reusable pen device.

Others in the market include Dr. Reddy's, Natco, Glenmark, Lupin, Torrent, USV and MSN. This list is a sample rather than a complete register, and availability varies by city and pharmacy.

The molecule is identical. DCGI approval requires demonstrated equivalence to the reference product, and several Indian manufacturers additionally ran Phase III studies in Indian patients before launch [6]. One company reported a head-to-head Phase III study in 312 participants showing non-inferior efficacy and a comparable safety profile to the originator [5].

What genuinely differs is everything around the molecule. Device format varies from disposable pens to reusable cartridge pens to vials needing a separate syringe. Not every brand carries the full 0.25 to 2.4 mg weight-management ladder; some cover only the diabetes range to 1 mg. Cold-chain handling and device quality can vary between manufacturers. And the originator carries the original global trial data package, which is where the STEP, SELECT and FLOW evidence on this page comes from.

Price is the most visible difference, several-fold, but it is the least clinically interesting one. Your doctor chooses on indication, dose range needed and which device you will actually use correctly every week.

They are different molecules, not different brands of the same thing, and no Indian generic of tirzepatide exists.

Semaglutide acts on one receptor, GLP-1. Tirzepatide acts on two, GIP and GLP-1, which is why it is called a dual agonist. In head-to-head trial data in type 2 diabetes, tirzepatide outperformed semaglutide 1 mg on both HbA1c and weight, and average weight reduction is higher with tirzepatide in the obesity trials as well.

Tirzepatide remains under patent in India with no generic expected for years, so it stays substantially more expensive than Indian semaglutide. Semaglutide, meanwhile, has a broader published outcomes evidence base in cardiovascular and kidney disease [2][3]. Which is right for you is a clinical decision made with your doctor, not a ranking. Read our tirzepatide page.

An approved product contains the same molecule and must meet the regulatory standards set for it, so clinical efficacy should be equivalent. The trial evidence and the side-effect rates on this page describe the molecule, and they apply whichever approved brand you are dispensed.

What we would genuinely watch is practical: whether the brand offers the dose range your indication needs, whether the device suits you, and whether the cold chain has been maintained between manufacture and your fridge. Buying from an unverified seller because it is cheaper still is where the real risk sits, not in the fact that a product is Indian-made.

Price alone is not a clinical reason to choose a product, and the cheapest option is not automatically the right one for you.

Switching between semaglutide products is usually straightforward because the molecule is the same, and it is normally done at an equivalent dose. It should still be a decision your doctor makes and documents, because device technique changes, the dose steps available may differ between brands, and a mid-titration switch needs planning.

Switching from tirzepatide to semaglutide is a different matter. The two are not dose-equivalent, so you restart semaglutide low and titrate up again. At Karespot we require a ten-day interval between your final tirzepatide dose and your first semaglutide dose, whereas many providers advise waiting 28 days. Speak to our Kare team before switching anything.

Semaglutide is a GLP-1 receptor agonist: a medicine that mimics glucagon-like peptide-1, a hormone your gut releases after eating to signal fullness, slow digestion and regulate insulin. Natural GLP-1 is broken down within minutes; semaglutide is engineered to last about a week, which is what makes a once-weekly injection possible.

In India it is approved for adults with type 2 diabetes and for chronic weight management as an adjunct to diet and exercise, in adults with obesity (BMI ≥ 30 kg/m²) or overweight (BMI ≥ 27 kg/m²) with weight-related comorbidities [6]. Since March 2026 it has been available from a large number of DCGI-approved Indian manufacturers as well as the imported originator [5][7].

Dose: a pre-filled pen typically contains 4 doses, each administered weekly or as per physician's guidance

Active Ingredient: Semaglutide

Drug class: GLP-1 receptor agonist

Application: To be injected subcutaneously in the abdomen, thigh, or upper arm

Indian manufacturers include: Sun Pharma (Noveltreat, Sematrinity), Eris Lifesciences (SUNDAE), Alkem Laboratories (Obesema, Semasize, Hepaglide) and Zydus Lifesciences (Semaglyn, Mashema, Alterme) [5][6][7]

Format note: products are supplied as pre-filled disposable pens, reusable cartridge pens or multi-dose vials requiring a separate syringe. Follow the instructions for the exact product you are dispensed.

• Supports meaningful weight reduction: an average of 14.9% of body weight over 68 weeks at the 2.4 mg dose, alongside lifestyle support [1].
• Helps improve blood sugar and lower A1C when used along with diet and exercise in adults with type 2 diabetes [6].
• Reduces the risk of major cardiovascular events in adults with established heart disease and overweight or obesity, without diabetes [2].
• Reduces the risk of major kidney events in adults with type 2 diabetes and chronic kidney disease [3].

Semaglutide can be injected into the abdomen or thigh. Choose an injection area that feels most comfortable. Rotate the injection spot every week by splitting the selected area into four sections and using a different section each time. Place each new injection at least a finger-width away from the previous one, and if injecting into the abdomen, keep the injection at least 5 cm away from the belly button.

• Consultation with a qualified Karespot doctor to assess your health profile and eligibility for prescription weight-loss treatment.
• Ongoing medical support to help you prevent and manage side effects safely.
• Daily check-ins from the Kare Team to track side effects, progress, nutrition, and sleep.
• Practical coaching to build sustainable habits around food, movement, and recovery.
• Discreet, fast home delivery: packed for privacy and shipped to your doorstep.

Before you proceed to checkout, please complete the eligibility check to confirm that you meet the basic criteria for the programme.

Once you move to payment, it means you've reviewed the eligibility requirements and would like to reserve your place in our limited-size programme. After payment, our clinical team will complete a medical review to confirm suitability.

If you are found ineligible during the medical review, we will refund your payment in full. Refunds are typically processed within 3–5 business days.

If you are found ineligible during the medical review, we will refund your payment in full. Refunds are typically processed within 3–5 business days.

In case you change your mind post consultation with the doctor, a nominal consultation fee of INR 500 will be charged and the balance amount will be refunded in 3–5 days.

• Do not use if you are allergic to semaglutide or any ingredients.
• Contraindicated for patients with Type 1 diabetes, severe kidney/liver disease, or a personal or family history of thyroid cancer (MTC/MEN 2).
• Consult your doctor if you are pregnant, breastfeeding, or taking other medications/supplements.
• Not suitable for individuals under 18 years of age.
• Exercise caution if you have a history of pancreatitis, gallbladder disease, or severe digestive issues.

The four most common, with their reported rates on the 2.4 mg dose against placebo in STEP 1 [1]:

• nausea — 44.2% vs 17.4%
• diarrhoea — 31.5% vs 15.9%
• vomiting — 24.8% vs 6.6%
• constipation — 23.4% vs 9.5%

Also reported: stomach pain, indigestion and reflux, burping and gas, bloating, dizziness, fatigue, headache, injection site reactions, and low blood sugar in people with type 2 diabetes. Gastrointestinal effects are the most common and usually appear or worsen around a dose increase, then settle.

• Alcohol: CONSULT YOUR DOCTOR
• Pregnancy: CONSULT YOUR DOCTOR
• Breastfeeding: CAUTION
• Driving: SAFE
• Kidney: SAFE IF PRESCRIBED
• Liver: SAFE IF PRESCRIBED

Yes. Semaglutide is a Schedule H, prescription-only medicine in India, and that has not changed with the arrival of cheaper Indian brands. It can only be dispensed against a valid prescription from a registered medical practitioner. A Karespot doctor can assess your eligibility in a ₹599 online consultation.

Semaglutide starts acting in the body soon after the first injection, though some people may not feel clear effects immediately. Because the starting dose of 0.25 mg is an initiation dose rather than a treatment dose, and titration to 2.4 mg takes about four months, meaningful weight change usually builds over months rather than weeks.

Weight-loss expectations

Some people feel appetite reduction early, while others only notice meaningful changes after moving to higher doses. Weight-loss speed varies widely between individuals and can be influenced by food choices, age, activity level, sleep and stress, and other medicines, so there isn't a single expected weekly rate that fits everyone.

Semaglutide has a half-life of about one week. After your final dose it can remain in the body for roughly five to seven weeks, with full clearance taking around eight to ten weeks depending on individual factors such as kidney function and general health. Over this period, its effects on appetite and blood sugar control fade gradually rather than stopping abruptly.

Semaglutide should be kept in the fridge at 2°C to 8°C. It must not be frozen or exposed to direct light. Storage rules once a pen or vial has been opened and started differ between products, so follow the instructions for the exact brand and format you are dispensed, and ask your Kare Team if you are unsure. Cold-chain handling matters as much as the brand you choose.

Start at the lowest dose, 0.25 mg once a week, and follow the advice shared by the doctor in your Kare team around dosage. Dose increases happen roughly every four weeks and are a medical decision. See the typical titration plan above, and never adjust your dose without your doctor.

Take your injection on the same day each week to keep levels steady. If you forget a dose, the next step depends on how much time has passed.

Missed-dose guidance

• If your next scheduled dose is more than 2 days away: take the missed dose as soon as you remember.
• If your next scheduled dose is less than 2 days away: skip the missed dose and take your next dose on your usual scheduled day.
• If you have missed semaglutide for more than 2 weeks, contact your prescribing clinician before restarting. You may need to restart at a lower dose.

If you are unsure about timing, or you have missed more than one dose, contact your prescribing clinician for individualised advice rather than guessing.

Often, yes, unless the underlying habits and metabolic drivers have been addressed. We would rather tell you that honestly upfront.

Obesity is a chronic, relapsing condition. Semaglutide works while you take it; when it stops, appetite signals return, and studies show a significant proportion of lost weight is regained over the following year.

This is precisely why Karespot pairs medication with dietician coaching, psychologist support and strength-based activity, so that when the medication ends, the habits and the muscle remain.